AlphaCore Capital’s Caris Life Sciences CAI Stock Holding History

AlphaCore Capital’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$360K	Buy	+11,751	New	+$264K	0.01%	995

Other funds holding CAI

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

AlphaCore Capital's CAI Position: Q3 2026 in Review

AlphaCore Capital opened a new position in Caris Life Sciences (CAI) in Q3 2026: 11,751 shares worth $360K. The stake represents 0.01% of the portfolio and ranks #995 among its holdings.

133 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

AlphaCore Capital held 11,751 shares of Caris Life Sciences worth $360K as of Q3 2026.
Caris Life Sciences was a new AlphaCore Capital position in Q3 2026.
Caris Life Sciences made up 0.01% of AlphaCore Capital's portfolio in Q3 2026, its #995 holding.
133 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.